Art

J-GLOBAL ID：201902215665734216   Reference number：19A0107978

Eribulin Treatment Induces High Expression of miR-195 and Inactivates the Wnt/β - catenin Signaling Pathway in Triple-negative Breast Cancer

エリブリン治療はトリプルネガティブ乳癌においてmiR-195の高発現を誘導しWnt/β-カテニンシグナル伝達経路を不活性化する

Author (15)： OKAZAKI Keinosuke (Department of Pharmacology, Showa University School of Medicine) ,  OKAZAKI Keinosuke (Department of Hospital Pharmaceutics, Showa University School of Pharmacy) ,  OKAZAKI Keinosuke (Department of Pharmacy, Division of Drug Information, Showa University Hospital) ,  SASAKI Akiko (Department of Pharmacology, Showa University School of Medicine) ,  TSUNODA Yuko (Kameda Medical Center, Breast Center) ,  FURUYA Kanji (Department of Pharmacology, Showa University School of Medicine) ,  FURUYA Kanji (Department of Orthopedic Surgery, Showa University Fujigaoka Hospital) ,  TSUJI Mayumi (Department of Pharmacology, Showa University School of Medicine) ,  UDAKA Yuko (Department of Pharmacology, Showa University School of Medicine) ,  OYAMADA Hideto (Department of Pharmacology, Showa University School of Medicine) ,  HOSONUMA Masahiro (Department of Pharmacology, Showa University School of Medicine) ,  SHIRAKO Haruna (Department of Pharmacology, Showa University School of Medicine) ,  YASUMOTO Taro (Department of Pharmacology, Showa University School of Medicine) ,  KIUCHI Yuji (Department of Pharmacology, Showa University School of Medicine) ,  SASAKI Tadanori (Department of Hospital Pharmaceutics, Showa University School of Pharmacy)
Material： Showa University Journal of Medical Sciences  (Showa Univ J Med Sci)
Volume： 30  Issue： 3  Page： 359-370(J-STAGE)  Publication year： 2018 
JST Material Number： L1154A  ISSN： 0915-6380  CODEN： SUMSEG  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： breast tumor ,...
Semi thesaurus term： cellular signal transduction ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A0107978&from=J-GLOBAL&jstjournalNo=L1154A") }}

Author keywords (5)： triple-negative breast cancer ,  eribulin ,  miR-195 ,  GSK-3β ,  Wnt/β -catenin signaling pathway

JST classification (3)： Basic research of antitumor(=antineoplastic)drugs  (GW16010A) ,  Cell physiology in general  (EF02010S) ,  Experimental treatment for tumors  (GE02040Y)

Substance index (1)： Eribulin

Reference (44)：

• 1) Brewster AM, Chavez-MacGregor M, Brown P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol. 2014;15:e625-e634.
• 2) Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750-2767.
• 3) Yao H, He G, Yan S, et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 2017;8:1913-1924.
• 4) Lehmann BD, Pietenpol JA. Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast. 2015;24 Suppl 2:S36-S40.
• 5) Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001;61:1013-1021.

Terms in the title (9)： エリブリン ,  治療 ,  トリプルネガティブ乳癌 ,  発現 ,  誘導 ,  Wnt ,  β-カテニン ,  シグナル伝達経路 ,  不活性化